Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy.

López-Cortés LF, Ruiz-Valderas R, Pascual R, Rodriguez M, Marín Niebla A.

HIV Clin Trials. 2003 May-Jun;4(3):227-9. No abstract available.

PMID:
12815561
2.

Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.

von Hentig N, Nisius G, Lennemann T, Khaykin P, Stephan C, Babacan E, Staszewski S, Kurowski M, Harder S, Haberl A.

Antivir Ther. 2008;13(8):1039-46.

PMID:
19195329
3.

Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.

López-Cortés LF, Ruiz-Valderas R, Viciana P, Mata R, Gómez-Vera J, Alarcón A, Pachón J.

J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):240-2. No abstract available.

PMID:
12571537
4.

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.

J Antimicrob Chemother. 2009 Dec;64(6):1260-4. doi: 10.1093/jac/dkp348. Epub 2009 Sep 22.

PMID:
19776037
5.

Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort.

Brunet C, Reliquet V, Jovelin T, Venisse N, Winer N, Bui E, Le Moal G, Perfezou P, De Saint Martin L, Raffi F.

Med Mal Infect. 2012 Sep;42(9):421-8. doi: 10.1016/j.medmal.2012.07.010. Epub 2012 Aug 28.

PMID:
22938775
6.

Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.

Rolla VC, da Silva Vieira MA, Pereira Pinto D, Lourenço MC, de Jesus Cda S, Gonçalves Morgado M, Ferreira Filho M, Werneck-Barroso E.

Clin Drug Investig. 2006;26(8):469-79.

PMID:
17163279
7.

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A.

Ther Drug Monit. 2007 Apr;29(2):171-6.

PMID:
17417070
8.

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70.

PMID:
11981362
9.

The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.

Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):921-8.

PMID:
15220698
10.

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

AIDS. 2000 Jun 16;14(9):F103-10.

PMID:
10894270
11.

The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.

HIV Med. 2005 Mar;6(2):122-8.

12.

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.

Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62.

13.

Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).

Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P.

Antivir Ther. 2004 Apr;9(2):247-56.

PMID:
15134187
14.

Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.

Kirk O, Mocroft A, Pradier C, Bruun JN, Hemmer R, Clotet B, Miller V, Viard JP, Phillips AN, Lundgren JD; EuroSIDA Study Group.

AIDS. 2001 May 25;15(8):999-1008.

PMID:
11399982
15.

Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.

Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M.

Antimicrob Agents Chemother. 2007 Jun;51(6):2035-42. Epub 2007 Mar 19.

16.

Saquinavir plus ritonavir reduce viral load by 99.9 percent.

Vazquez E.

Posit Aware. 1996 Nov-Dec;7(6):8-9.

PMID:
11363983
17.

The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study.

Rhone SA, Hogg RS, Yip B, Sherlock C, Conway B, Schechter MT, O'Shaughnessy MV, Montaner JS.

AIDS. 1998 Apr 16;12(6):619-24.

PMID:
9583602
18.

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.

Churchill DR, Pym AS, Galpin S, Foxall R, Stainsby C, Clarke JR, Kaye S, Bloor S, Larder BA, Wills B, Sun E, Babiker AG, Back DJ, Weber JN.

AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1181-9.

PMID:
10480631
19.
20.

Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients.

Merry C, Barry MG, Mulcahy F, Tjia JF, Halifax KL, Heavey J, Kelly C, Back DJ.

AIDS. 1998 Feb 12;12(3):325-7. No abstract available.

PMID:
9517997

Supplemental Content

Support Center